IntroductionBimekizumab is a monoclonal antibody that targets Interleukin-17 A and F, approved for the treatment of moderate-to-severe plaque psoriasis. While bimekizumab has been evaluated in several phase-III clinical trials, real-world evidence is still very limited.MethodThis multicenter retrospective study included patients affected by plaque psoriasis treated with bimekizumab from May 1, 2022 to April 30, 2023, at 19 Italian referral hospitals. Patients affected by moderate-to-severe plaque psoriasis eligible for systemic treatments were included. The effectiveness of bimekizumab was evaluated in terms of reduction in psoriasis area and severity index (PASI) compared with baseline at weeks 4 and 16. The main outcomes were the percentages of patients achieving an improvement of at least 75% (PASI75), 90% (PASI90) and 100% (PASI100) in PASI score.ResultsThe study included 237 patients who received at least one injection of bimekizumab. One hundred and seventy-one patients and 114 reached four and 16 weeks of follow-up, respectively. Complete skin clearance was achieved by 43.3% and 75.4% of patients at weeks 4 and 16, respectively. At week 16, 86.8% of patients reported no impact on their quality of life. At week 16, there were no significant differences between bio-naïve and bio-experienced patients in terms of PASI75, PASI90 and PASI100. The most commonly reported adverse events (AEs) were oral candidiasis (10.1%). No severe AEs or AEs leading to discontinuation were observed throughout the study.ConclusionOur experience supports the effectiveness and tolerability of bimekizumab in a real-world setting with similar results compared with phase-III clinical trials.

undetected primary gonadal GCT which may have regressed spontaneously, especially a testicular tumor. [1][2][3] Primary and metastatic (also called secondary) germ cell tumors account for approximately one quarter of all retroperitoneal tumors. 2,3 For both primary and secondary tumors, serum tumor marker detection could help with diagnosis (e.g., alpha-fetoprotein, human chorionic gonadotropin), as well as they are markers of tumor relapse. 2,3 However, the existence of the so-called primary EGCT of the retroperitoneum is still a matter of debate, 3,4 and they should be considered to be metastases of a viable or burned-out testicular cancer until proven otherwise. 1,3 Both extragonadal and gonadal germ cell tumors involving the skin are extremely rare, and when they occur, most lesions are true mature teratomas. 4 The prognosis is variable according to the disease extension and systemic dissemination. 4 Curative treatment is achieved after wide excision whenever it is possible. Chemotherapy and radiotherapy are recommended as adjuvant to surgery and for metastatic disease. 4 To date, there is one report of malignant primary EGCT located in the scalp in a child and another report of a mixed nonseminomatous germ cell tumor presenting as a subcutaneous tissue mass. 1,5 Cutaneous EGCT can be difficult to differentiate from a primary malignant neoplasm, sarcoma, or a skin metastasis. Dermatologists must be attentive in order to early recognize cutaneous manifestations of EGCT to increase the suspicion of these rare presentations of this life-threatening disease.

No abstract

No abstract

Psoriasis (PSO) and Atopic dermatitis (AD) are common inflammatory skin diseases that affect people of all ages globally. They negatively impact the quality of life (QoL) of patients in health-related aspects such as physical, psychological and mental functioning. Here, we conducted a review of studies relating to candidate biomarkers and indicators associated with QoL impairment in PSO and AD. Data research was performed using PUBMED and SCOPUS databases from inception to September 2022. Most of the included studies reported genomic or proteomic biomarkers associated with disease activity and QoL outcomes. Sociodemographic, clinical and therapeutic factors have also been implicated in deterioration of life quality in these patients. The inclusion of clinical characteristics, QoL impairment and co-diagnosis should be considered in drug development programs, since processing biomarkers based on an increased number of features in addition to drug class and disease will intensify the value of the biomarker itself, thereby maximizing the future clinical utility as a stratification tool.